OSE Immunotherapeutics to receive up to 155 million euros over Janssen's FR104 development

5 July 2016

Janssen Biotech, a European subsidiary of US healthcare giant Johnson & Johnson (NYSE: JNJ), has exercised an option within its global licensing agreement with France-based OSE Immunotherapeutics (OSE: EN Paris) to take on the development of FR104.

This product is a monoclonal antibody fragment and antagonist of CD28, a key receptor in effector T lymphocytes, with preclinical proof of concept demonstrated in autoimmune diseases and transplantation. It has been developed by Effimune, which became OSE Immunotherapeutics on merging with OSE Pharma only a month ago.

Under the terms of the agreement, Janssen will be responsible for all clinical development, registration and commercialization activities for FR104, internationally, in the areas of autoimmune diseases and transplantation. The deal was facilitated by Effimune and Johnson & Johnson Innovation’s London Innovation Centre in October 2013.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK